A PHASE II OPEN-LABEL MULTI-COHORT MULTICENTER STUDY IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA AND CHILD-PUGH B7 AND B8 CIRRHOSIS

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Unresectable Hepatocellular Carcinoma
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Locally advanced or metastatic and/or unresectable HCC with diagnosis confirmed by histology/cytology
    2. Disease that is not amenable to curative surgical and/or locoregional therapies
    3. No prior systemic treatment (including systemic investigational agents) for locally advanced or metastatic and/or unresectable HCC

You may not be eligible for this study if the following are true:

    1. Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti -CTLA-4, anti-PD-1, anti-PD-L1, and anti-TIGIT therapeutic antibodies
    2. Treatment with investigational therapy within 28 days prior to initiation of study treatment
    3. Treatment with locoregional therapy to liver (e.g., radiofrequency ablation, percutaneous ethanol, or acetic acid injection, cryoablation, high-intensity focused ultrasound, transarterial chemoembolization, transarterial embolization) within 28 days prior to initiation of study treatment, or non-recovery from side effects of any such procedure



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.